Skip to main content

Table 2 The effect of IVIG therapy on the primary and secondary prognostic endpoints

From: Intravenous immunoglobulin-based adjuvant therapy for severe COVID-19: a single-center retrospective cohort study

Parameter

Total

n = 113

Non-IVIG

n = 66

IVIG

n = 47

P

P*

Composite end point

17 (15.0%)

5 (7.6%)

12 (25.5%)

0.008

0.167

Death

13 (11.5%)

4 (6.1%)

9 (19.1%)

0.032

Mechanical ventilation

11 (9.7%)

1 (1.5%)

10 (21.3%)

< 0.001

Length of hospital stay

20.0 (15.0–25.0)

16.0 (13.8–22.0)

23.0 (19.0–31.0)

< 0.001

0.041

  1. *Corrected by age, sex, comorbidities, maximum body temperature, WBC, LYM, AST, PT, DD and use of glucocorticoids